Low-Dose Splenic Irradiation in the Treatment of Immune Thrombocytopenia in HIV-Infected Patients

Abstract

Purpose: To determine the effect of low-dose splenic irradiation on severe Zidovudine-resistant, HIV-1–associated thrombocytopenia (HAT). Methods and Materials: Between September 1994 and October 1996, 17 patients were included in a prospective study. The patients met the following criteria for inclusion: hemorrhagic symptoms or a platelet count below or equal to 50 × 10 9/l and normal numbers of megakaryocytes on bone aspiration. The mean baseline platelet count was 20.3 (± 14.4) × 10 9/l; four patients had a platelet count inferior to 10 × 10 9/l. Splenic volume was defined by ultrasonography. A total dose of 9 Gy was given using an isocentric parallel pair field technique. Results: One month after the end of treatment six patients had a significant rise in their platelet count. Clinically, hemorrhagic symptoms stopped for all patients that were symptomatic. Unfortunately, duration of response was short because for one patient only the platelet count remains stable with a follow-up of 6 months. All patients are alive and in recent evaluation, with four out of eight patients receiving a combination of antiretroviral therapy had a platelet count above 50 × 10 9/l. Conclusion: Our results are disappointing concerning the duration of response, especially comparatively to those reported in autoimmune thrombocytopenia. Mechanisms of HAT are more complex, and megakaryocytes’ infection may play an important role. Splenic irradiation should be considered as palliative treatment for the minority of patients with severe bleeding that does not respond to standard medical treatment.